| Document |
Document Title |
|
WO/2022/145405A1 |
Provided is pharmaceutical composition for treating a viral respiratory tract infection, characterized by combining a compound represented by formula (I) or a pharmaceutically acceptable salt thereof and a cap-dependent endonuclease inhi...
|
|
WO/2022/145407A1 |
Provided is a medicinal composition for treating viral respiratory tract infections, said medicinal composition being characterized by comprising a combination of a compound represented by formula (I) or a pharmaceutically acceptable sal...
|
|
WO/2022/138988A1 |
The present invention provides a compound exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. Further provided are crystals that are...
|
|
WO/2022/136339A1 |
The present invention pertains to the use of conjugated fumonisin (FUM) in a method to protect an animal against FUM induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, intestinal damage, live...
|
|
WO/2022/138549A1 |
Provided is a nintedanib-containing solid dispersion in which the amount of impurities originating from nintedanib contained therein is low. The present invention provides a solid dispersion containing the components (a) and (b) indica...
|
|
WO/2022/140457A1 |
The disclosure provides methods of treating a tissue, organ, organoid or organ culture, the method comprising treating a tissue, organ, organoid or organ culture in vitro with a composition comprising one or more cell turnover factors pr...
|
|
WO/2022/135072A1 |
Provided in the present invention are a coumarin compound, a preparation method therefor, and the use and a pharmaceutical composition thereof, belonging to the technical field of medicines. The coumarin compound provided in the present ...
|
|
WO/2022/138257A1 |
The present invention provides a new substance having a PDE5 inhibitory effect. This PDE5 inhibitor includes a pupae powder or an extract thereof.
|
|
WO/2022/138923A1 |
A purpose of the present invention is to provide a novel ceramide synthesis promoter. The present invention relates to a ceramide synthesis promoter including alkaline ionized water obtained by electrolyzing an aqueous solution including...
|
|
WO/2022/138944A1 |
The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the f...
|
|
WO/2022/138075A1 |
The purpose of the present invention is to provide an eye drop-type eyewash composition and the like having excellent antiseptic properties. This eye drop-type eyewash composition contains 0.005-0.03 w/v% of allantoin and does not contai...
|
|
WO/2022/138792A1 |
The purpose of the present invention is to provide a suitable form for a compound, and an active pharmaceutical ingredient thereof, for the prevention and/or treatment of a disease associated with the activation of an EP2 receptor, said ...
|
|
WO/2022/138987A1 |
The present invention provides a compound exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. Further provided are crystals that are...
|
|
WO/2022/138984A1 |
The present invention provides a neurite outgrowth promoter for promoting neurite growth on nerve cells of a postnatal mammalian individual for use in a condition in which an effective amount of a glial cell-derived neurotrophic factor (...
|
|
WO/2022/138793A1 |
The present application addresses the problem of providing an effective cancer treatment method. Provided is a combination between: a compound represented by general formula (I-A) (in the formula, all signs represent the same as those ...
|
|
WO/2022/137644A1 |
[Problem] To find and provide beneficial bacteria from the flora in the birth canal. [Solution] An aspect of the present disclosure is a strain DL81 bacterium belonging to the species Lactobacillus coleohominis, which has been internatio...
|
|
WO/2022/133551A1 |
The present application is directed towards compounds, pharmaceutically acceptable salts or prodrugs thereof, which are inhibitors of Histone Deacetylase (HDAC) binding or function. The compounds especially may have some selectivity for ...
|
|
WO/2022/138791A1 |
The purpose of the present invention is to provide a medicine for the prevention and/or treatment of a disease caused by activation of an EP2 receptor, said medicine containing, as an active ingredient, a compound having an antagonistic ...
|
|
WO/2022/140654A1 |
The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts thereof.
|
|
WO/2022/140248A1 |
A nutritional supplement composition formulated to minimize DNA damage and improve DNA repair includes Folate, Vitamin B12, Vitamin D and Zinc.
|
|
WO/2022/138258A1 |
The present invention provides a new substance having a PDE5 inhibitory effect. This PDE5 inhibitor includes Paecilomyces tenuipes powder or an extract thereof.
|
|
WO/2022/137964A1 |
The present invention provides a pharmaceutical composition for preventing or treating cartilage/bone/joint diseases, the pharmaceutical composition containing, as active ingredients, a substance that inhibits the signal transduction of ...
|
|
WO/2022/138938A1 |
The present invention provides a spherical culture for which quantitative analysis can be easily performed for a region including brain neurons, which is useful as a supply source of neurons for transplantation, and which can be suitably...
|
|
WO/2022/135523A1 |
Disclosed in the present invention is an application of a BMP4 protein in preparation of a drug for treating or preventing a fibroproliferative disease of an object, wherein the BMP4 protein is a free BMP4 protein or a recombinant vector...
|
|
WO/2022/138888A1 |
The purpose of the present invention is to provide a compound having a tetrahydroquinoline skeleton, said compound having ferroptosis inhibitory action and exhibiting a treatment effect or a prevention effect for a disease, disorder, or ...
|
|
WO/2022/138866A1 |
[Problem] To provide an agent for improving atopic dermatitis that exhibits a high therapeutic effect and has few side effects on the skin. [Solution] The agent contains erythritol and is characterized by being applied topically to the s...
|
|
WO/2022/136640A1 |
The present invention relates to an active pharmaceutical ingredient selected from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-c
arboximidoyl chloride, its stereoisomers and the acid addition salts thereof; specifically ar...
|
|
WO/2022/140253A1 |
A nutritional supplement composition formulated having antioxidant and anti-inflammatory nutrients reduces cellular biomarkers of DNA damage and improves cellular regenerative capacity.
|
|
WO/2022/138692A1 |
The present invention provides an antigen-binding molecule (e.g. antibody) with improved cytosol-penetrating ability, the molecule comprising an amino acid substitutions on at least one selected from the group consisting of CDRL1, CDRL2 ...
|
|
WO/2022/136348A1 |
The present invention pertains to the use of conjugated T-2 toxin (T2) in a method to protect an animal against T2 induced mycotoxicosis, in particular to protect against a decrease in average daily weight gain, intestinal damage, skin d...
|
|
WO/2022/136343A1 |
The present invention pertains to the use of conjugated zearalenone (ZEA) in a method to protect an animal against ZEA induced mycotoxicosis, in particular to protect against decreased weight gain, kidney damage, liver damage and damage ...
|
|
WO/2022/138871A1 |
[Problem] To provide a skin-disease improvement agent that is capable of effectively suppressing a skin disease in which a bacterium such as Staphylococcus aureus or a multidrug-resistant strain thereof is involved, in a simple, safe, an...
|
|
WO/2022/133027A1 |
Compounds of formula (1) wherein R1 represents a -C(R2)(R3)-[C(R4)(R5)]m-L-R6 group or -R7; and the preparation and the therapeutic uses of the compounds of formula (1) as agonists of TRPM8 receptors, useful especially in the treatment o...
|
|
WO/2022/131081A1 |
[Problem] The purpose of the present invention is to provide an emulsified composition that is for external application, that contains urea and a salicylic acid-based anti-inflammatory agent, and that can suppress degradation of urea and...
|
|
WO/2022/131192A1 |
This composition comprises a lactic acid bacteria belonging to the genus Lactobacillus, and intake of the composition by a subject improves inflammation in the brain tissue of the subject.
|
|
WO/2022/131114A1 |
Provided is a novel polypeptide. A polypeptide according to one embodiment of the present invention is a polypeptide comprising an amino acid sequence shown by SEQ ID NO: 1 or 3, or is a variant thereof. A polypeptide according to anothe...
|
|
WO/2022/126948A1 |
A traditional Chinese medicine composition for treating an indirect hernia, and a preparation method therefor and the use thereof. The raw materials of the composition are spiders, Cinnamomi ramulus, Bupleuri radix, Astragali radix, Cimi...
|
|
WO/2022/131198A1 |
A combination drug for treating kidney caner, said combination drug comprising a tyrosine kinase inhibitor combined with a dipeptidyl peptidase 4 inhibitor; and a therapeutic effect enhancer for a tyrosine kinase inhibitor, said therapeu...
|
|
WO/2022/130290A1 |
The disclosure provides compositions and methods of treating diseases and conditions associated with phospholipase D (PLD) toxin. In particular, the methods include administering to a subject in need a pharmaceutical composition comprisi...
|
|
WO/2022/131108A1 |
The present disclosure relates to a substance and a composition that are effective in improving skin elasticity and wrinkles from the standpoint of maintaining or improving quality of life (QOL) in terms of both health and beauty. More s...
|
|
WO/2022/131282A1 |
Provided is a soap, disinfectant, bactericide or sterilizer for cleaning, and detergent that contains a natural ingredient and an extract thereof, the safety of which has been confirmed even after many years of being eaten, as a main com...
|
|
WO/2022/129543A1 |
The present invention proposes a gene therapy approach as a potential curative treatment for the USHER syndrome, in particular for the USH1G syndrome, which is characterized by a profound deafness and a severe vestibular defect in humans...
|
|
WO/2022/131063A1 |
The purpose of the present invention is to provide a composition for improving muscle flexibility. The present invention relates to a composition for improving muscle flexibility that contains quercetin and/or a glycoside thereof.
|
|
WO/2022/130732A1 |
Provided is a hygiene product derived from seaweeds and an extract thereof, for oral cavity, nostrils, or throat. This hygiene product for the oral cavity or nostrils includes a mouth washing liquid and a cleaning agent for the oral ca...
|
|
WO/2022/133110A1 |
Disclosed herein are epithelial cell adhesion molecule (EpCAM)-specific binding polypeptides. These binding polypeptides may be incorporated into chimeric antigen receptors (CARs). Also disclosed herein are methods of using these binding...
|
|
WO/2022/131080A1 |
[Problem] To provide an emulsified composition for external use that comprises urea and a salicylic acid-based anti-inflammatory agent and that can suppress phase separation and decomposition of urea due to storage. [Solution] An emulsif...
|
|
WO/2022/131322A1 |
A purpose of the present invention is to develop and provide a neuron activator for activating brain neurons. Another purpose of the present invention is to provide an agent for accelerating, when cell transplantation is performed for a ...
|
|
WO/2022/131283A1 |
Provided are a food and drinking water that contain a natural material or an extract thereof, said natural material having physiologic and medicinal effects and thus being capable of preventing infection with multiple viruses and sterili...
|
|
WO/2022/131350A1 |
The purpose of the present invention is to overcome problems in the acquisition of a DNA aptamer in the conventional methods, including the lack of variety of interactions with target molecules, the increase in the cost for aptamer acqui...
|
|
WO/2022/128057A1 |
Suggested are agonists of olfactory receptors, particularly OR2AT4, showing (i) a molecular weight ranging from about 50 to about 300 Dalton and (ii) an evaporation rate versus butyl acetate of about 3 to about 15 for use as a medicament...
|
